DETERMINE precision medicine trial
DETERMINE is the first UK national precision medicine trial in rare cancers.
Led by the University of Manchester and sponsored and managed by Cancer Research UK's Centre for Drug Development, DETERMINE is a multi-drug, precision medicine trial for adults, teenagers and children with rare cancers. It is run in collaboration with the University of Birmingham, the Royal Marsden NHS Foundation Trust and the Christie NHS Foundation Trust.
DETERMINE is a trial open in the UK and is expected to recruit until 2027. This trial is exploring whether treatments approved for use in some cancer types can target identifiable genetic alterations in other types. It also provides new treatments options for those who might not have any left.
Drugs which show promising results will be accelerated for Cancer Drug Fund assessment and NHS approval.
How to join DETERMINE
For patients
Taking part in the trial is a personal decision. Speak to your doctor if you're interested in participating.
For clinicians
Learn more about patient eligibility, referrals, practicing sites across the UK and treatment arms.
For partners
Find out about the benefits of becoming a commercial partner, meet our team and more.
Meet our investigators
Dr Matthew Krebs
Chief Investigator
University of Manchester
Dr Krebs is a medical oncologist with expertise in precision medicine. He is responsible for the medical, scientific and strategic oversight of the DETERMINE platform. He is also the Chief Investigator of the TARGET Precision Medicine program, which is a major route for patent identification for DETERMINE.
Dr Lynley Marshall
Paediatric Lead
Royal Marsden Hospital
Dr Marshall is a paediatric oncologist with expertise in drug development. She is responsible for overseeing the medical and scientific aspects of the DETERMINE study with respect to children and young people.
Professor Gary Middleton
Translational Lead
University of Birmingham
Professor Middleton is a medical oncologist with expertise in the genomic, transcriptomic and immunological context underlying response to targeted therapy. He is Translational Lead for the DETERMINE study and will coordinate academic research at the Universities of Manchester and Birmingham and the Institute of Cancer Research.
Professor Lucinda Billingham
Statistical Lead
University of Birmingham
Professor Billingham is a biostatistician with an interest in cancer research. She is responsible for the design and statistical analysis of the DETERMINE study.
With the potential to change outcomes for adults, teenagers and children with rare cancers, this trial will be ground-breaking for a patient population who often feel neglected by current cancer research.
— Dr Matthew Krebs, Chief investigator, DETERMINE trial
Meet our collaborators
University of Manchester
The DETERMINE trial is led and managed by the University of Manchester.
Centre for Drug Development
The DETERMINE trial is sponsored and managed by Cancer Research UK's Centre for Drug Development.
University of Birmingham
The DETERMINE trial is run in collaboration with the University of Birmingham.
The Royal Marsden NHS Foundation Trust
The DETERMINE trial is run in collaboration with the The Royal Marsden NHS Foundation Trust.
Our participating sites
Open sites for adults
England
1. Manchester: The Christie Hospital
2. Birmingham: University Hospital
3. Bristol: Haematology and Oncology Cancer Centre
4. Cambridge: Addenbrookes Hospital
5. Leicester: Leicester Royal Infirmary
6. Liverpool
7. London: Guy's Hospital
8. London: University College London Hospital
9. Newcastle upon Tyne: Freeman Hospital
10. Oxford: Churchill Hospital
11. Sheffield: Weston Park Hospital
12. Southampton
Wales
13. Cardiff: Velindre Cancer Centre
Scotland
14. Edinburgh: Western General Hospital
15. Glasgow: The Beatson Cancer Centre
Northern Ireland
16. Belfast: Health and Social Care Trust
Open sites for paediatrics, teenagers and young adults
England
1. London/Surrey: Royal Marsden Hospital
2. Bristol: The Bristol Royal Hospital for children
3. Cambridge: Addenbrookes Hospital
4. Liverpool: Alder Hey
5. London: Great Ormond Street Hospital
6. Manchester: in set up
7. Newcastle upon Tyne: Great North Children Hospital
8. Oxford: John Radcliffe Hospital
9. Sheffield: Sheffield Children Hospital
Wales
10. Cardiff: in set up
Scotland
11. Glasgow: The Royal Hospital for Children Glasgow
Northern Ireland
Coming soon
Other things you may be interested in
Our latest news
Discover more about the DETERMINE precision medicine trial through our latest press releases, articles, awards and network updates.
Experimental Cancer Medicine Centres Network (ECMC)
DETERMINE is delivered through the ECMC network, which supports Cancer Research UK, industry, other funders and partners with early phase trials.
PRIME-ROSE
DETERMINE is part of PRIME-ROSE, which aims to broaden patient access to a wider range of innovative precision cancer medicine treatments by connecting similar clinical trials.